How has this study helped patients and researchers?
The results from this study showed that The side effects reported in this study did not
amounts of antibodies were higher after 2 raise any safety concerns. There were no serious
injections of the 2-type vaccine than of the 4- side effects reported in this study.
type vaccine. Higher antibody amounts may give
This summary only shows results from one
better protection from the viruses.
study. Other studies may find different results.
Are there plans for further studies?
At the time of preparation of this summary, other studies of the 2-type HPV vaccine were planned
and/or ongoing. The results of these studies will be available on GlaxoSmithKline’s Study Register (See
link at the end of this document).
Where can I find more information about this study?
The detailed title for this research study is:
A Phase IIIb observer-blind, randomized, multi-centre primary immunization study to evaluate the
immunogenicity and safety of GSK Biologicals’ HPV-16/18 L1 VLP AS04 vaccine and Merck's Quadrivalent
Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine, when administered intramuscularly
according to alternative 2-dose schedules in 9-14 year old healthy females.
Organization Website Study Number
European Medicines Agency www.clinicaltrialsregister.eu 2011-002035-26
United States National Institutes www.clinicaltrials.gov NCT01462357
of Health (NIH)
GlaxoSmithKline (GSK) www.gsk.clinicalstudyregister.com 115411
Your doctor can help you understand more about this study and the results. You should not make
changes to your care based on the results of this or any single study. Keep taking your current
treatment unless instructed by your doctor.
This document was developed and approved by GSK on 25 July 2018. The information in this summary
does not include additional information available after this date.
For readers of this document in text form, the websites associated with the hyperlinks above are:
EudraCT summary:
https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-002035-26/SE
US NIH/clinicaltrials.gov:
https://clinicaltrials.gov/ct2/show/NCT01462357?term=115411&rank=1
GSK Clinical Study Register:
https://www.gsk-clinicalstudyregister.com/study/115411?search=study&#ps